2) In this program we are covering @myESMO #ESMO22 updates on #HER2 mutant #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD) from @IEOufficiale, Milan in Italy 🇮🇹 pic.twitter.com/8Rm1MxsPC7
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
3b) This content is intended for healthcare providers. ✔️accreditation statement & faculty disclosures at https://t.co/0EkFYkmuR5.
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
5a) Recently, different anti-HER2 drugs, including target agents & #ADCs, showed promising data in many different clinical trials, indicating that #HER2 mutations in # NSCLC should be screened & targeted & serve as a critical clinical decision–making tool https://t.co/d4nGeyxB79 pic.twitter.com/ZHe3vWVHIa
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
6a) T-DM1, ado-trastuzumab emtansine, was the first #ADC evaluated. In 18 pretreated patients with #HER2-mutant lung adenocarcinoma, investigators showed an ORR of 44% and a mPFS of 5 months.
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
7) After T-DM1, development of trastuzumab deruxtecan (#T_DXd) was initiated in #lungcancer with #HER2 mutations. T-DXd is an #ADC consisting of a humanized anti-HER2 mAb linked to a topo-I inhibitor payload through a cleavable linker https://t.co/HioPRzXePx pic.twitter.com/dc8Io5zsnI
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
9) The results 🔓https://t.co/lVDGUFTaq0 showed ORR of 55%, mDoR of 9.3 m, mPFS & mOS of 8.2 and 17.8 m, respectively. Efficacy was consistent across distinct subgroups, including pts who had previously received a #HER2-directed TKI & those with brain mets #LCSM pic.twitter.com/U5pCJFeCKi
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
11a) 🆕At #ESMO22, updated results from #DESTINY_Lung01 were presented. No new safety concerns were identified & for efficacy, mOS in the previously treated T-DXd cohort ⬆️to 18.6mos. ORR was 54.9% and DCR 92.3% among 91 pts evaluated. pic.twitter.com/zo4LHQnvwL
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
12a) 🆕During #ESMO22, Koichi Goto presented the results of ph 2 non-comparative #DESTINY_Lung2 trial, evaluating the efficacy and safety of 2 doses of T-DXd (5.4 and 6.4 mg/kg) in previously treated pts with metastatic #NSCLC harbouring #HER2 mutations. pic.twitter.com/hXceTxclix
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
12c) Treatment-emergent adverse events (#TEAEs) were higher with T-DXd 6.4 mg/kg vs 5.4 mg/kg in the prespecified early cohort (PEC) and safety analysis set (SAS) (median treatment duration: 4.7/5.5 mo and 3.3/3.7 mo). pic.twitter.com/1A2iVnRF4X
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
14a) The results presented by Goto et al during #ESMO22, confirmed that the T-DXd at the lower dose of 5.4 mg/kg showed a clinical meaningful response in pretreated pts with NSCLC harbouring HER2 mutations . . . pic.twitter.com/HQIt530SGI
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
15) So in a patient with metastatic non-Sq #NSCLC, with #HER2 mutation, with disease progression after Carboplatin-Pemetrexed q3w, which treatment is best 2L?
— pulmmed_ce (@Pulmmed_CE) October 26, 2022
a. Trastuzumab deruxtecan 6.4 mg/kg
b. Docetaxel q3w
c. Trastuzumab deruxtecan 5.4 mg/kg
d. T-DM1
16) You're now caught up on the highlights from #ESMO22 on advances in #HER2-mut #NSCLC. Click on https://t.co/95GoBdfzPE and grab your certificate for 🆓CE/#CME . . . and FOLLOW US for more expert-led 🫁 education on Twitter! I am @APassaroMD and I 🙏you for joining us!
— pulmmed_ce (@Pulmmed_CE) October 26, 2022